Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Tango Therapeutics (TNGX) Non Operating Income: 2020-2024

Historic Non Operating Income for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $15.5 million.

  • Tango Therapeutics' Non Operating Income fell 52.14% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.9 million, marking a year-over-year decrease of 39.86%. This contributed to the annual value of $15.5 million for FY2024, which is 23.39% up from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Non Operating Income is $15.5 million, which was up 23.39% from $12.6 million recorded in FY2023.
  • Tango Therapeutics' Non Operating Income's 5-year high stood at $15.5 million during FY2024, with a 5-year trough of -$248,000 in FY2021.
  • In the last 3 years, Tango Therapeutics' Non Operating Income had a median value of $12.6 million in 2023 and averaged $10.3 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first slumped by 208.77% in 2021, then skyrocketed by 1,289.11% in 2022.
  • Yearly analysis of 5 years shows Tango Therapeutics' Non Operating Income stood at $228,000 in 2020, then tumbled by 208.77% to -$248,000 in 2021, then skyrocketed by 1,289.11% to $2.9 million in 2022, then spiked by 326.01% to $12.6 million in 2023, then increased by 23.39% to $15.5 million in 2024.